INTERPACE BIOSCIENCES, INC. (IDXG) Net margin 2016–2025
INTERPACE BIOSCIENCES, INC. (IDXG) net profit margin by fiscal year — reported net income divided by reported revenue.
63.5%FY2025 · since FY2016: -168.2% → 63.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 63.5% | +49.2 pp |
| FY2024 | 14.3% | +9.4 pp |
| FY2023 | 4.9% | +73.8 pp |
| FY2022 | -69.0% | -23.8 pp |
| FY2021 | -45.1% | +36.5 pp |
| FY2020 | -81.6% | +28.8 pp |
| FY2019 | -110.4% | -52.4 pp |
| FY2018 | -58.0% | -137.0 pp |
| FY2017 | 79.0% | +247.1 pp |
| FY2016 | -168.2% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More IDXG financial trends
IDXG RevenueIDXG Net incomeIDXG Gross profitIDXG Gross marginIDXG Operating incomeIDXG Operating marginIDXG Operating cash flowIDXG Free cash flowIDXG Capital expendituresIDXG Return on equityIDXG Stock buybacksIDXG Dividends paidIDXG Total assetsIDXG Total liabilitiesIDXG Shareholders’ equityIDXG overview →